AstraZeneca exceeds sales and profits forecast amid coronavirus, outlook unchanged
Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.
Product sales, which exclude payments from tie-ups, rose 9 percent to $6.05 billion in the three months ended June 30 on a constant-currency basis, surpassing analysts’ consensus of $6.01 billion.
Core earnings stood at 96 cents per share versus analysts’ estimate of 93 cents. Total revenue rose 11 percent, AstraZeneca said.